SecurityLJPC / La Jolla Pharmaceutical Co. (503459604)
President, CEO & SecretaryTIDMARSH GEORGE F
Form 4 Count95
Form 8-K Count81
Form SC 13G/A Count35
Form 10-Q Count19

SEC Filings - 10K, 8K, Annual Reports

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to La Jolla Pharmaceutical Co.


DateFormTitle
2018-05-14 8-K LJPC / La Jolla Pharmaceutical Co. 8-K (Current Report)
2018-05-10 10-Q LJPC / La Jolla Pharmaceutical Co. 10-Q (Quarterly Report)
2018-04-30 10-K/A LJPC / La Jolla Pharmaceutical Co. 10-K/A (Annual Report)
2018-04-06 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / BlackRock Inc. - null (Passive Investment)
2018-04-06 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / BlackRock Inc. - null (Passive Investment)
2018-03-27 CT ORDER LJPC / La Jolla Pharmaceutical Co. null
2018-03-20 SC 13D/A LJPC / La Jolla Pharmaceutical Co. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 10 (Activist Investment)
2018-03-20 SC 13D/A LJPC / La Jolla Pharmaceutical Co. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 10 (Activist Investment)
2018-03-19 8-K LJPC / La Jolla Pharmaceutical Co. FORM 8-K (Current Report)
2018-03-16 424B5 LJPC / La Jolla Pharmaceutical Co. 424B5 (Prospectus)
2018-03-14 424B5 LJPC / La Jolla Pharmaceutical Co. 424B5 (Prospectus)
2018-03-01 SC 13D/A LJPC / La Jolla Pharmaceutical Co. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 9 (Activist Investment)
2018-03-01 SC 13D/A LJPC / La Jolla Pharmaceutical Co. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 9 (Activist Investment)
2018-02-22 10-K LJPC / La Jolla Pharmaceutical Co. 10-K (Annual Report)
2018-02-14 SC 13G LJPC / La Jolla Pharmaceutical Co. / Consonance Capital Management LP - CONSONANCE CAPITAL MANAGEMENT LP (Passive Investment)
2018-02-14 SC 13G LJPC / La Jolla Pharmaceutical Co. / Consonance Capital Management LP - CONSONANCE CAPITAL MANAGEMENT LP (Passive Investment)
2018-02-14 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / RTW INVESTMENTS, LLC - 3G/A (Passive Investment)
2018-02-14 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / RTW INVESTMENTS, LLC - 3G/A (Passive Investment)
2018-02-13 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / FMR LLC / Fidelity - 3G/A (Passive Investment)
2018-02-13 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / FMR LLC / Fidelity - 3G/A (Passive Investment)
2018-02-07 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / FRANKLIN RESOURCES INC - 3G/A (Passive Investment)
2018-02-07 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / FRANKLIN RESOURCES INC - 3G/A (Passive Investment)
2018-02-06 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / JANUS CAPITAL MANAGEMENT LLC - JANUS CAPITAL MANAGEMENT 12/31/17 <5% ANNUAL CLOSEOUT (Passive Investment)
2018-02-06 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / JANUS CAPITAL MANAGEMENT LLC - JANUS CAPITAL MANAGEMENT 12/31/17 <5% ANNUAL CLOSEOUT (Passive Investment)
2018-02-05 SC 13G LJPC / La Jolla Pharmaceutical Co. / JENNISON ASSOCIATES LLC - 13G INITIAL ANNUAL FILING - IJPC (Passive Investment)
2018-02-05 SC 13G LJPC / La Jolla Pharmaceutical Co. / JENNISON ASSOCIATES LLC - 13G INITIAL ANNUAL FILING - IJPC (Passive Investment)
2018-02-01 SC 13G LJPC / La Jolla Pharmaceutical Co. / BlackRock Inc. - 3G (Passive Investment)
2018-02-01 SC 13G LJPC / La Jolla Pharmaceutical Co. / BlackRock Inc. - 3G (Passive Investment)
2018-01-30 8-K LJPC / La Jolla Pharmaceutical Co. 8-K (Current Report)
2018-01-26 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / PRUDENTIAL FINANCIAL INC - 3G/A (Passive Investment)
2018-01-26 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / PRUDENTIAL FINANCIAL INC - 3G/A (Passive Investment)
2018-01-11 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / Broadfin Capital, LLC - 3G/A (Passive Investment)
2018-01-11 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / Broadfin Capital, LLC - 3G/A (Passive Investment)
2018-01-11 SC 13G LJPC / La Jolla Pharmaceutical Co. / Broadfin Capital, LLC - 3G (Passive Investment)
2018-01-11 SC 13G LJPC / La Jolla Pharmaceutical Co. / Broadfin Capital, LLC - 3G (Passive Investment)
2017-12-31 8-K LJPC / La Jolla Pharmaceutical Co. 8-K (Current Report)
2017-12-28 8-K LJPC / La Jolla Pharmaceutical Co. 8-K (Current Report)
2017-12-18 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 1 TO SCHEDULE 13G (Passive Investment)
2017-12-18 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 1 TO SCHEDULE 13G (Passive Investment)
2017-12-31 CORRESP LJPC / La Jolla Pharmaceutical Co. ESP
2018-01-01 LETTER LJPC / La Jolla Pharmaceutical Co. ER
2017-10-30 8-K La Jolla Pharmaceutical 8-K (Current Report/Significant Event)
2017-10-28 S-3 La Jolla Pharmaceutical FORM S-3
2017-10-28 S-8 La Jolla Pharmaceutical S-8
2017-10-27 10-Q La Jolla Pharmaceutical 10-Q (Quarterly Report)
2017-10-10 SC 13G La Jolla Pharmaceutical 3G (Passive Acquisition of More Than 5% of Shares)
2017-10-10 SC 13G La Jolla Pharmaceutical 3G (Passive Acquisition of More Than 5% of Shares)
2017-09-30 8-K La Jolla Pharmaceutical 8-K (Current Report/Significant Event)
2017-09-06 8-K La Jolla Pharmaceutical 8-K (Current Report/Significant Event)
2017-08-29 8-K La Jolla Pharmaceutical 8-K (Current Report/Significant Event)

Related Articles

HIMX: Himax Technologies Analysis and Research Report

7h - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

CUSIP: 503459604